Tatva Chintan Pharma Chem Ltd
Tatva Chintan Pharma Chem Limited was incorporated in 1996 and it is a manufacturer of a diverse portfolio of structure Directing Agents, Phase Transfer Catalysts, electrolyte salts for batteries, and Pharmaceutical and Agrochemical Intermediates and other Speciality chemicals[1]
- Market Cap ₹ 3,324 Cr.
- Current Price ₹ 1,413
- High / Low ₹ 1,469 / 610
- Stock P/E 237
- Book Value ₹ 313
- Dividend Yield 0.07 %
- ROCE 0.26 %
- ROE 0.05 %
- Face Value ₹ 10.0
Pros
- Company has been maintaining a healthy dividend payout of 245%
Cons
- Stock is trading at 4.51 times its book value
- The company has delivered a poor sales growth of 7.62% over past five years.
- Company has a low return on equity of 4.03% over last 3 years.
- Promoter holding has decreased over last 3 years: -7.15%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Part of BSE SmallCap BSE Allcap BSE Commodities
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| 131 | 203 | 254 | 291 | 428 | 403 | 379 | 366 | 417 | |
| 110 | 170 | 201 | 226 | 322 | 348 | 312 | 340 | 367 | |
| Operating Profit | 22 | 33 | 53 | 65 | 106 | 55 | 67 | 26 | 50 |
| OPM % | 16% | 16% | 21% | 22% | 25% | 14% | 18% | 7% | 12% |
| 2 | 1 | 1 | 5 | 11 | 2 | 7 | 3 | 4 | |
| Interest | 3 | 4 | 4 | 4 | 5 | 9 | 7 | 1 | 2 |
| Depreciation | 3 | 4 | 5 | 7 | 8 | 10 | 26 | 28 | 32 |
| Profit before tax | 18 | 26 | 44 | 59 | 103 | 39 | 42 | 0 | 19 |
| Tax % | 38% | 24% | 21% | 13% | 7% | -4% | 31% | 28% | |
| 11 | 20 | 35 | 51 | 96 | 40 | 29 | 0 | 14 | |
| EPS in Rs | 13.74 | 25.13 | 43.51 | 25.57 | 43.31 | 18.26 | 12.55 | 0.14 | 5.98 |
| Dividend Payout % | 0% | 0% | 0% | 20% | 5% | 11% | 16% | 709% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 8% |
| 3 Years: | -5% |
| TTM: | 17% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -60% |
| 3 Years: | -84% |
| TTM: | 5% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -17% |
| 1 Year: | 61% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 10% |
| 3 Years: | 4% |
| Last Year: | 0% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 20 | 22 | 22 | 23 | 23 | 23 |
| Reserves | 51 | 72 | 106 | 142 | 447 | 483 | 702 | 698 | 710 |
| 56 | 77 | 91 | 90 | 120 | 170 | 14 | 36 | 83 | |
| 29 | 31 | 40 | 58 | 87 | 80 | 75 | 65 | 90 | |
| Total Liabilities | 145 | 187 | 245 | 310 | 676 | 755 | 815 | 823 | 906 |
| 57 | 67 | 111 | 120 | 160 | 196 | 427 | 529 | 515 | |
| CWIP | 10 | 6 | 5 | 10 | 51 | 231 | 77 | 24 | 80 |
| Investments | 1 | 1 | 1 | 1 | 1 | 1 | 11 | 1 | 1 |
| 76 | 114 | 129 | 179 | 464 | 327 | 301 | 269 | 310 | |
| Total Assets | 145 | 187 | 245 | 310 | 676 | 755 | 815 | 823 | 906 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| 25 | 19 | 20 | 24 | 103 | 24 | |||
| -40 | -21 | -197 | -101 | -121 | -65 | |||
| 10 | -5 | 235 | 38 | 31 | 17 | |||
| Net Cash Flow | -6 | -6 | 58 | -40 | 13 | -25 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 92 | 80 | 73 | 113 | 53 | 82 | 66 | 76 |
| Inventory Days | 134 | 98 | 165 | 168 | 299 | 249 | 313 | 228 |
| Days Payable | 132 | 70 | 88 | 116 | 82 | 52 | 96 | 60 |
| Cash Conversion Cycle | 94 | 109 | 150 | 166 | 269 | 278 | 282 | 244 |
| Working Capital Days | 16 | 46 | 45 | 73 | 72 | 22 | 154 | 139 |
| ROCE % | 22% | 27% | 28% | 26% | 8% | 7% | 0% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
2d - Newspaper Publication of Extract of Financial Results of the Company for the quarter and half year ended 30 September 2025.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
2d - Earnings call recording from 31 October 2025 available on Tatva Chintan website.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
31 Oct - Investor Presentation for the quarter and half year ended 30 September 2025.
-
Intimation Under Regulation 30 (5) Of The SEBI ("SEBI") (LODR) Regulations, 2015
31 Oct - Board on 31 Oct 2025 authorised five KMPs to determine materiality and make SEBI disclosures.
-
Announcement under Regulation 30 (LODR)-Change in Management
31 Oct - Unaudited Q2/H1 results approved; CFO Ajesh Pillai appointed effective 31 Oct 2025.
Annual reports
Concalls
-
Oct 2025TranscriptNotesPPT REC
-
Jul 2025Transcript PPT REC
-
May 2025Transcript PPT
-
Jan 2025Transcript PPT
-
Oct 2024Transcript PPT
-
Jul 2024Transcript PPT REC
-
May 2024Transcript PPT REC
-
Jan 2024Transcript PPT REC
-
Nov 2023Transcript PPT REC
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Jan 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Jul 2022Transcript PPT
-
Apr 2022Transcript PPT
-
Jan 2022Transcript PPT
-
Oct 2021TranscriptPPT
-
Sep 2021TranscriptPPT
Product Portfolio
The company has a portfolio of 214 products divided into 4 categories: [1]